Kamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma.
The company’s portfolio includes 6 FDA-approved plasma-derived products, which are distributed in over 30 international markets.
The company's headquarters and laboratories are located in the park of Kiryat Weizmann Institute of Science in Rehovot, Israel. The production facility is located in Kibbutz Beit Kama, Israel. The company also has offices in the United States, located in Hoboken, New Jersey.
History
Kamada was founded in 1990 by David Tzur, Ralph Hahn and Kamapharam Ltd., which was wholly owned by Kibbutz Beit Kama, until then Kamapharam was producing albumin, and its production facilities were acquired in full by Kamada In 1999, (35%) to a company owned by Hahn and another investor for $2.5 million. Hahn and Tzur headed the company by the beginning of 2013. The company completed its first public offering in 2005 on the Tel Aviv Stock Exchange.[1]
Today, the company specializes in the development, manufacture and marketing of proteins, especially for orphan diseases. The company produces about 10 injectable and marketed drugs in more than 15 countries around the world.